While early observational metrics show the FDA commissioner physically vacating his office, public health officials urge the public not to draw definitive conclusions until peer-reviewed confirmation is available.
WASHINGTON — Preliminary observational data gathered early this week suggests that Marty Makary has departed his role as commissioner of the Food and Drug Administration, though public health experts are strongly cautioning against drawing any definitive conclusions until peer-reviewed confirmation is published.
According to a pre-print analysis circulated by researchers at the Johns Hopkins Bloomberg School of Public Health, methodologists observed a statistically significant correlation between Makary handing in his government-issued badge on Tuesday and his subsequent failure to appear at Wednesday morning’s interagency steering committee meeting. However, biostatisticians were quick to note that the findings are based on a highly localized sample size of just one (n=1) federal departure, leaving the study vulnerable to numerous confounding variables such as traffic, a long lunch, or a miscalibrated Outlook calendar.
"We are seeing early, unadjusted hazard ratios indicating that Dr. Makary is packing up his office," read a cautiously worded editorial accompanying the data in The Lancet Public Health. "But as with any observational study, we must differentiate between association and causation. It is entirely possible that his resignation letter and his sudden physical absence from the FDA campus are two independent events occurring simultaneously by chance."
While the data demonstrating Dr. Makary is no longer employed by the federal government is compelling, we must remember this is a retrospective cohort of just one resignation, and we lack a control group to determine if he would have left the building anyway.
The research team also disclosed that they have not yet ruled out reverse causation, suggesting that Makary’s absence from the building could theoretically have caused the resignation letter to spontaneously generate on his desk. The authors noted a potential conflict of interest, as several researchers rely on the FDA for grant funding and therefore have a vested interest in someone eventually being in charge of it.
Meanwhile, secondary endpoints in the ongoing political health monitor have flagged Senator Bill Cassidy’s Senate seat as increasingly "tenuous." Epidemiologists tracking the Louisiana Republican’s approval metrics warned that while the confidence intervals are widening, drawing a direct line between recent health policy shifts and Cassidy’s electoral prognosis requires further longitudinal follow-up. The authors emphasized that the senator's political vulnerability was entirely self-reported, which traditionally introduces recall bias.
Until randomized, double-blind trials can definitively prove that Makary is not secretly still running the agency from a remote location, experts recommend that Americans proceed with their standard bureaucratic protocols and consult with their primary care physician before assuming the FDA has a vacancy.